Percutaneous Metallic Stents in Patients with Obstructive Jaundice due to Hepatocellular Carcinoma

Hyun Pyo Hong, Seung Kwon Kim, Tae-Seok Seo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: To evaluate the technical success and clinical efficacy of percutaneously placed self-expandable metallic stents in patients with obstructive jaundice due to hepatocellular carcinoma (HCC). Materials and Methods: Fifteen men (mean age, 59.3 years) with obstructive jaundice resulting from HCC were treated with self-expandable metallic stents (28 stents in 19 sessions). The authors evaluated the technical success, clinical success (decrease of 30% of total serum bilirubin level or <2 mg/dL [34.2 μmol/L]), treatment efficacy according to lowest total serum bilirubin level, complications, and duration of stent patency. Results: Technical success was achieved in all patients. Clinical success was achieved in 11 of the 15 patients (73%). After stent placement, seven patients (47%) had a low bilirubin level (<2 mg/dL [34.2 μmol/L]), three (20%) had an intermediate bilirubin level (2-10 mg/dL [34.2-171 μmol/L]), and five (33%) had a high bilirubin level (>10 mg/dL [171 μmol/L]). A low bilirubin level was achieved in all patients with Child-Pugh A disease and stage T2 or T3 HCC. Major complications such as hemobilia necessitating transfusion (n = 1) or abscess formation (n = 1) occurred in two of the 19 sessions (10%). The overall mean stent patency was 149.8 days (range, 12-790 days). The mean stent patency in patients with Child-Pugh class A disease (257.8 days) was significantly longer than that of patients with Child-Pugh class B and C disease (123.2 and 63 days, respectively) (P < .05). Conclusions: The percutaneous placement of a self-expandable metallic stent is a feasible and effective palliative treatment for patients with obstructive jaundice resulting from HCC, especially for those with Child-Pugh class A disease and stage T2 or T3 HCC.

Original languageEnglish
Pages (from-to)748-754
Number of pages7
JournalJournal of Vascular and Interventional Radiology
Volume19
Issue number5
DOIs
Publication statusPublished - 2008 May 1

Fingerprint

Obstructive Jaundice
Stents
Hepatocellular Carcinoma
Bilirubin
Hemobilia
Palliative Care
Abscess
Serum
Self Expandable Metallic Stents

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Percutaneous Metallic Stents in Patients with Obstructive Jaundice due to Hepatocellular Carcinoma. / Hong, Hyun Pyo; Kim, Seung Kwon; Seo, Tae-Seok.

In: Journal of Vascular and Interventional Radiology, Vol. 19, No. 5, 01.05.2008, p. 748-754.

Research output: Contribution to journalArticle

@article{5085635e538f4b27922042d3508cae74,
title = "Percutaneous Metallic Stents in Patients with Obstructive Jaundice due to Hepatocellular Carcinoma",
abstract = "Purpose: To evaluate the technical success and clinical efficacy of percutaneously placed self-expandable metallic stents in patients with obstructive jaundice due to hepatocellular carcinoma (HCC). Materials and Methods: Fifteen men (mean age, 59.3 years) with obstructive jaundice resulting from HCC were treated with self-expandable metallic stents (28 stents in 19 sessions). The authors evaluated the technical success, clinical success (decrease of 30{\%} of total serum bilirubin level or <2 mg/dL [34.2 μmol/L]), treatment efficacy according to lowest total serum bilirubin level, complications, and duration of stent patency. Results: Technical success was achieved in all patients. Clinical success was achieved in 11 of the 15 patients (73{\%}). After stent placement, seven patients (47{\%}) had a low bilirubin level (<2 mg/dL [34.2 μmol/L]), three (20{\%}) had an intermediate bilirubin level (2-10 mg/dL [34.2-171 μmol/L]), and five (33{\%}) had a high bilirubin level (>10 mg/dL [171 μmol/L]). A low bilirubin level was achieved in all patients with Child-Pugh A disease and stage T2 or T3 HCC. Major complications such as hemobilia necessitating transfusion (n = 1) or abscess formation (n = 1) occurred in two of the 19 sessions (10{\%}). The overall mean stent patency was 149.8 days (range, 12-790 days). The mean stent patency in patients with Child-Pugh class A disease (257.8 days) was significantly longer than that of patients with Child-Pugh class B and C disease (123.2 and 63 days, respectively) (P < .05). Conclusions: The percutaneous placement of a self-expandable metallic stent is a feasible and effective palliative treatment for patients with obstructive jaundice resulting from HCC, especially for those with Child-Pugh class A disease and stage T2 or T3 HCC.",
author = "Hong, {Hyun Pyo} and Kim, {Seung Kwon} and Tae-Seok Seo",
year = "2008",
month = "5",
day = "1",
doi = "10.1016/j.jvir.2007.12.455",
language = "English",
volume = "19",
pages = "748--754",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Percutaneous Metallic Stents in Patients with Obstructive Jaundice due to Hepatocellular Carcinoma

AU - Hong, Hyun Pyo

AU - Kim, Seung Kwon

AU - Seo, Tae-Seok

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Purpose: To evaluate the technical success and clinical efficacy of percutaneously placed self-expandable metallic stents in patients with obstructive jaundice due to hepatocellular carcinoma (HCC). Materials and Methods: Fifteen men (mean age, 59.3 years) with obstructive jaundice resulting from HCC were treated with self-expandable metallic stents (28 stents in 19 sessions). The authors evaluated the technical success, clinical success (decrease of 30% of total serum bilirubin level or <2 mg/dL [34.2 μmol/L]), treatment efficacy according to lowest total serum bilirubin level, complications, and duration of stent patency. Results: Technical success was achieved in all patients. Clinical success was achieved in 11 of the 15 patients (73%). After stent placement, seven patients (47%) had a low bilirubin level (<2 mg/dL [34.2 μmol/L]), three (20%) had an intermediate bilirubin level (2-10 mg/dL [34.2-171 μmol/L]), and five (33%) had a high bilirubin level (>10 mg/dL [171 μmol/L]). A low bilirubin level was achieved in all patients with Child-Pugh A disease and stage T2 or T3 HCC. Major complications such as hemobilia necessitating transfusion (n = 1) or abscess formation (n = 1) occurred in two of the 19 sessions (10%). The overall mean stent patency was 149.8 days (range, 12-790 days). The mean stent patency in patients with Child-Pugh class A disease (257.8 days) was significantly longer than that of patients with Child-Pugh class B and C disease (123.2 and 63 days, respectively) (P < .05). Conclusions: The percutaneous placement of a self-expandable metallic stent is a feasible and effective palliative treatment for patients with obstructive jaundice resulting from HCC, especially for those with Child-Pugh class A disease and stage T2 or T3 HCC.

AB - Purpose: To evaluate the technical success and clinical efficacy of percutaneously placed self-expandable metallic stents in patients with obstructive jaundice due to hepatocellular carcinoma (HCC). Materials and Methods: Fifteen men (mean age, 59.3 years) with obstructive jaundice resulting from HCC were treated with self-expandable metallic stents (28 stents in 19 sessions). The authors evaluated the technical success, clinical success (decrease of 30% of total serum bilirubin level or <2 mg/dL [34.2 μmol/L]), treatment efficacy according to lowest total serum bilirubin level, complications, and duration of stent patency. Results: Technical success was achieved in all patients. Clinical success was achieved in 11 of the 15 patients (73%). After stent placement, seven patients (47%) had a low bilirubin level (<2 mg/dL [34.2 μmol/L]), three (20%) had an intermediate bilirubin level (2-10 mg/dL [34.2-171 μmol/L]), and five (33%) had a high bilirubin level (>10 mg/dL [171 μmol/L]). A low bilirubin level was achieved in all patients with Child-Pugh A disease and stage T2 or T3 HCC. Major complications such as hemobilia necessitating transfusion (n = 1) or abscess formation (n = 1) occurred in two of the 19 sessions (10%). The overall mean stent patency was 149.8 days (range, 12-790 days). The mean stent patency in patients with Child-Pugh class A disease (257.8 days) was significantly longer than that of patients with Child-Pugh class B and C disease (123.2 and 63 days, respectively) (P < .05). Conclusions: The percutaneous placement of a self-expandable metallic stent is a feasible and effective palliative treatment for patients with obstructive jaundice resulting from HCC, especially for those with Child-Pugh class A disease and stage T2 or T3 HCC.

UR - http://www.scopus.com/inward/record.url?scp=42649113727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42649113727&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2007.12.455

DO - 10.1016/j.jvir.2007.12.455

M3 - Article

VL - 19

SP - 748

EP - 754

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 5

ER -